Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
bemnifosbuvir + rosuvastatin + ruzasvir
- Development stage
- Unknown
- Lead developer
- Atea Pharmaceuticals
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Rosuvastatin + BEM/RZR refers to the co-administration of the marketed statin rosuvastatin with the investigational fixed-dose combination (FDC) of bemnifosbuvir (BEM) and ruzasvir (RZR). This combination was evaluated in a Phase 1 drug-drug interaction (DDI) study (NCT06921941) conducted by Atea Pharmaceuticals. Bemnifosbuvir is a nucleotide analog that inhibits the Hepatitis C virus (HCV) NS5B RNA-dependent RNA polymerase, and ruzasvir is an inhibitor of the HCV NS5A protein. Rosuvastatin, an HMG-CoA reductase inhibitor, serves as a probe substrate for the BCRP and OATP1B1 transporters in this study to assess the impact of the BEM/RZR FDC on the pharmacokinetics of co-administered drugs. The BEM/RZR FDC is being developed as an oral, once-daily regimen for the treatment of chronic HCV infection.
- Brand names
- Crestor
- Other names
- rosuvastatin + BEM/RZRbemnifosbuvir/ruzasvir + rosuvastatinbemnifosbuvir + ruzasvir + rosuvastatin
02
Targets
NS5B (Hepatitis C virus non-structural protein 5B (NS5B) RNA-dependent RNA polymerase)NS5A (Hepatitis C virus nonstructural protein 5A (genotype 1b))HMGCR (3-hydroxy-3-methylglutaryl-coenzyme A reductase)
Beyond the preview
Go deeper on bemnifosbuvir + rosuvastatin + ruzasvir.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on bemnifosbuvir + rosuvastatin + ruzasvir.